Mixed Phase IIb results for Santhera's Parkinson drug
01 July 2009
Asher Mullard
Please Login to read the full article.
01 July 2009
Asher Mullard
asher.mullard@informa.com
Santhera Pharmaceuticals' Phase IIb trial of fipamezole (JP-1730) failed to meet its primary endpoint, but the drug did show promise in a subpopulation of Parkinson's patients. Preliminary results of the trial indicate that fipamezole is safe and well tolerated, says the Swiss company.
The...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck Serono safinamide boomerang 'completely unexpected' by Newron acquisitor BioTie
- GSK and Impax nearing US and European regulatory filings for Parkinson's drug
- Investors give XenoPort 5% nudge on SPA deal with US FDA
- Addex sends allosteric modulator into Phase II for Parkinson's
FEATURES
- DKSH highlights one-stop benefits as it builds Asia market expansion services
- Interview: Adimab's Gerngross seeks two sweethearts
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
